| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 6 securities · passive | ||||||
|
Replimune Group, Inc.
13G/A
REPL · 76029N106
|
8.7%
Checked 5% or less
|
8/14/2026
Event 6/30/2026
|
||||
| Ridgeback Capital Investments L.P. | 8.7% | |||||
| Ridgeback Capital Investments LLC | 8.7% | |||||
| Ridgeback Capital Management LLC | 8.7% | |||||
|
Lenz Therapeutics, Inc.
13G/A
LENZ · 52635N103
|
0% |
2/17/2026
Event 12/31/2025
|
||||
| Ridgeback Capital Investments L.P. | 0% | |||||
| Ridgeback Capital Investments LLC | 0% | |||||
| Ridgeback Capital Management LLC | 0% | |||||
|
Semler Scientific, Inc.
13G/A
SMLR · 81684M104
|
0% |
11/14/2025
Event 9/30/2025
|
||||
| Ridgeback Capital Investments L.P. | 0% | |||||
| Ridgeback Capital Investments LLC | 0% | |||||
| Ridgeback Capital Management LLC | 0% | |||||
|
iTeos Therapeutics, Inc.
13G/A
ITOS · 46565G104
|
0% |
11/14/2025
Event 9/30/2025
|
||||
| Ridgeback Capital Investments L.P. | 0% | |||||
| Ridgeback Capital Investments LLC | 0% | |||||
| Ridgeback Capital Management LLC | 0% | |||||
|
Affimed N.V.
13G/A
AFMDQ · N01045207
|
0% |
5/20/2025
Event 5/16/2025
|
||||
| Ridgeback Capital Investments L.P. | 0% | |||||
| Ridgeback Capital Investments LLC | 0% | |||||
| Ridgeback Capital Management LLC | 0% | |||||
|
Pyxis Oncology, Inc.
13G/A
PYXS · 747324101
|
0.6% |
2/14/2025
Event 12/31/2024
|
||||
| Ridgeback Capital Investments L.P. | 0.6% | |||||
| Ridgeback Capital Investments LLC | 0.6% | |||||
| Ridgeback Capital Management LLC | 0.6% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.